Micropam (Diazepam)

Diazepam binds to a specific site on the GABA‑A receptor complex, enhancing the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx, hyperpolarising neurons and reducing excitability, which produces anxiolytic, anticonvulsant, muscle‑relaxant and sedative actions.

The appropriate dose of Micropam is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Dosage may vary for anxiety, seizure control, muscle spasm, or alcohol‑withdrawal management, and should follow local prescribing guidelines.

Safety data for rectal diazepam in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks to the fetus or infant, and use the product only if clearly indicated. Consultation with a specialist is recommended before prescribing to pregnant or nursing women.

To request Micropam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Micropam delivers diazepam via the rectal route, offering rapid absorption compared with oral tablets. Compared with alternatives such as lorazepam or clonazepam, diazepam has a longer half‑life, which may reduce dosing frequency but can prolong sedation. Choice of agent depends on clinical context, required onset, and duration of action.

Micropam should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures. Keep out of reach of children and ensure the rectal applicator remains sealed until use.

Micropam is supplied as a rectal preparation. The prescribed dose is placed into the rectum using the provided applicator, allowing the medication to be absorbed through the rectal mucosa. Administration should be performed according to the healthcare professional’s instructions to ensure proper dosing and efficacy.

Serious adverse events include respiratory depression, paradoxical agitation (increased anxiety or aggression), and the development of physical dependence leading to withdrawal syndrome upon abrupt discontinuation. Patients should be monitored closely for these reactions, especially when used with other central nervous system depressants.

Micropam is contraindicated in patients with known hypersensitivity to diazepam or other benzodiazepines, those with severe respiratory insufficiency, acute narrow‑angle glaucoma, and individuals with severe hepatic impairment. Caution is also advised for the elderly, pregnant women, and patients with a history of substance abuse.